No Data
No Data
The synthetic biology concept strengthened in the afternoon, with Channing Biotech, Shengda Biotech, Blue Bio, and Yiduoli rising and stopping, while Lukang Pharmaceutical, Hanyu Pharmaceutical, and Meihua Biotech followed suit.
The synthetic biology concept strengthened in the afternoon, with Channing Biotech, Shengda Biotech, Blue Bio, and Yiduoli rising and stopping, while Lukang Pharmaceutical, Hanyu Pharmaceutical, and Meihua Biotech followed suit.
The synthetic biology concept rose and spread in the afternoon. Shengda Biotech pulled up and stopped, and Jin Dawei, Zhejiang Zhenyuan, and Hanyu Pharmaceutical assisted in the back row.
The synthetic biology concept rose and spread in the afternoon. Shengda Biotech pulled up and stopped, and Jin Dawei, Zhejiang Zhenyuan, and Hanyu Pharmaceutical assisted in the back row.
The A-share synthetic biology concept boosted Azure Biotech in a straight line
Gelonghui, April 26 | The synthetic biology concept in the A-share market fluctuated and increased. Blue Biotech went up and down, Shengda Biotech shook up and down, and Olin Biotech, Kaiser Biotech, and Bonne Group followed suit. According to the news, Tan Tianwei, an Academician of the Chinese Academy of Engineering, said at the 2024 Zhongguancun Forum annual meeting that biomantry is a new track and new business format where new quality productivity is very important. Currently, under the leadership of the Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry of Science and Technology, and other national ministries and departments are jointly developing a national biotechnology and biomaneling action plan, which is expected to be introduced in the near future.
Shengda Biotech (603079.SH): Net loss of 54.062,900 yuan in 2023
Gelonghui, April 19 | Shengda Biotech (603079.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 727 million yuan, a year-on-year decrease of 1.44%; net profit attributable to shareholders of listed companies - 54.629 million yuan; and basic earnings per share - 0.32 yuan. The company plans to distribute a cash dividend of 0.60 yuan (tax included) for every 10 shares to all shareholders.
Express News | Shengda Biotech: Net profit of 3.813 million yuan in the first quarter of 2024 increased 9.22% year-on-year
Sunda Biotech (603079.SH): A total of 1.09% of shares have been repurchased
Gelonghui, April 1, 丨 Shengda Biotech (603079.SH) announced that by the end of March 2024, the company had repurchased a total of 1.872,500 shares through centralized bidding transactions, accounting for 1.09% of the company's total share capital. The highest purchase price was 13.38 yuan/share, the lowest price was 7.428 yuan/share, and the total amount paid was 22.784 million yuan (excluding transaction fees such as stamp duty and transaction commissions).
No Data